CITATION REPORT
List of articles citing

The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19

#	Paper	IF	Citations
69	Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. *Clinical Science*, **2021**, 135, 465-481	6.5	23
68	The Pleiotropic Function of Human Sirtuins as Modulators of Metabolic Pathways and Viral Infections. *Cells*, **2021**, 10,	7.9	6
67	Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. *Bosnian Journal of Basic Medical Sciences*, **2021**, 21, 515-527	3.3	1
66	IFN-and TNF-drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. *Genome Medicine*, **2021**, 13, 64	14.4	47
65	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. *Current Rheumatology Reports*, **2021**, 23, 28	4.9	7
64	The Prospects of tumor necrosis factor Inhibitors use in patients with COVID-19. *Sovremennaya Revmatologiya*, **2021**, 15, 89-93	0.7	
63	COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. *Current Medical Research and Opinion*, **2021**, 37, 929-938	2.5	4
62	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. *Journal of Inflammation Research*, **2021**, 14, 1487-1510	4.8	26
61	Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. *Biomedicines*, **2021**, 9,	4.8	7
60	Anti-TNF-agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling. *Frontiers in Immunology*, **2021**, 12, 641295	8.4	11
59	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. *International Journal of Rheumatic Diseases*, **2021**, 24, 733-745	2.3	8
58	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. **2021**, 9,		17
57	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. *Current Opinion in Rheumatology*, **2021**, 33, 412-418	5.3	2
56	COVID-19: a pandemic challenging healthcare systems. *IISE Transactions on Healthcare Systems Engineering*, 1-22	1.3	1
55	The role of immunomodulatory medications in the treatment of COVID-19. *Current Opinion in Rheumatology*, **2021**, 33, 431-445	5.3	1
54	Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19. *PLoS ONE*, **2021**, 16, e0254374	3.7	2
53	Executable Network of SARS-CoV-2-Host Interaction Predicts Drug Combination Treatments.		

52	Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. *Biomedicine and Pharmacotherapy*, **2021**, 140, 111785	7.5	5
51	Pathogenesis and treatment of cytokine storm in COVID-19. *Turkish Journal of Biology*, **2021**, 45, 372-389.	3.1	3
50	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks. *Annals of the Rheumatic Diseases*, **2021**,	2.4	
49	Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. *Journal of Autoimmunity*, **2021**, 122, 102683	15.5	15
48	The COVID-19 Pandemic and Rheumatology: Impact on Providing Care in Latin America and Around the World. *Journal of Rheumatology*, **2021**, 48, 1501-1503	4.1	
47	The Role of the PFNA Operon of Bifidobacteria in the Recognition of Host's Immune Signals: Prospects for the Use of the FN3 Protein in the Treatment of COVID-19. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
46	Multi-layered transcriptomic analyses reveal an immunological overlap between COVID-19 and hemophagocytic lymphohistiocytosis associated with disease severity.		2
45	Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19. *Cytokine*, **2021**, 148, 155719	4	1
44	Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. *PLoS ONE*, **2021**, 16, e0258271	3.7	1
43	The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case-control study. *Inflammopharmacology*, **2021**, 29, 1769-1776	5.1	6
42	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. *JAMA Network Open*, **2021**, 4, e2129639	10.4	17
41	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. *Journal of Leukocyte Biology*, **2021**, 110, 1225-1239	6.5	1
40	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. *RMD Open*, **2021**, 7,	5.9	2
39	Network Meta-analysis on the Changes of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. *Journal of NeuroImmune Pharmacology*, **2021**, 16, 756	6.9	3
38	Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. *Clinical Rheumatology*, **2021**, 1	3.9	4
37	COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges.. *Cells*, **2021**, 10,	7.9	7
36	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. *RMD Open*, **2021**, 7, e001896	5.9	4
35	Blocking TNF signaling may save lives in COVID-19 infection.. *Molecular Biology Reports*, **2022**, 49, 2303	2.8	4

34	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.. *Journal of Biomedical Science*, **2022**, 29, 1	13.3	17
33	The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs.. *Frontiers in Immunology*, **2021**, 12, 797390	8.4	2
32	Identifying absorbable bioactive constituents of yupingfeng powder acting on COVID-19 through integration of UPLC-Q/TOF-MS and network pharmacology analysis.. *Chinese Herbal Medicines*, **2022**,	1.4	2
31	TNF-Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection.. *Microbiology Spectrum*, **2022**, e0141121	8.9	
30	Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.. *Lancet Respiratory Medicine,the*, **2021**,	35.1	6
29	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.. *Nature Reviews Rheumatology*, **2022**,	8.1	9
28	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.. *Nature Communications*, **2022**, 13, 946	17.4	2
27	Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance.. *Frontiers in Physiology*, **2021**, 12, 793251	4.6	2
26	Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States.. *Cells*, **2022**, 11,	7.9	3
25	A Web Application for Biomedical Text Mining of Scientific Literature Associated with Coronavirus-Related Syndromes: Coronavirus Finder.. *Diagnostics*, **2022**, 12,	3.8	
24	COVID-19 therapeutics: Challenges and directions for the future.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2119893119	11.5	9
23	Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome.. *Mediators of Inflammation*, **2022**, 2022, 7137900	4.3	0
22	Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.. *Frontiers in Immunology*, **2021**, 12, 789317	8.4	0
21	Immune dysfunction in COVID-19 and judicious use of anti-rheumatic drugs for the treatment of hyperinflammation. *Turkish Journal of Medical Sciences*, **2021**,	2.7	1
20	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.. *Pharmaceuticals*, **2021**, 14,	5.2	2
19	Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19.. *Journal of Cell Communication and Signaling*, **2022**, 1	5.2	
18	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. *Pharmaceuticals*, **2022**, 15, 616	5.2	1
17	The role of cytokines and their antagonists in the treatment of COVID-19 patients. *Reviews in Medical Virology*,	11.7	0

16	Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.		0
15	Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy. *Annals of Saudi Medicine*, **2022**, 42, 155-164	1.6	
14	A Vicious Cycle: In Severe and Critically Ill COVID-19 Patients. *Frontiers in Immunology*, 13,	8.4	1
13	Biopharmaceuticals for prevention of COVID-19: A scoping review. *Asian Pacific Journal of Tropical Medicine*, **2022**, 15, 245	2.1	1
12	Brain region-specific microglial and astrocytic activation in response to systemic lipopolysaccharides exposure. 14,		1
11	A novel logical model of COVID-19 intracellular infection to support therapies development. **2022**, 18, e1010443		0
10	Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS. **2022**, 18, e1010819		0
9	Anti-TNF Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients. **2022**, 12, 1770		0
8	Role of CCL2/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table. **2022**, 113, 109325		1
7	Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). **2022**, 27,		1
6	Severe COVID-19 May Impact Hepatic Fibrosis /Hepatic Stellate Cells Activation as Indicated by a Pathway and Population Genetic Study. **2023**, 14, 22		0
5	Efficacy and safety evaluation of dexmedetomidine for postoperative patient controlled intravenous analgesia: A systematic review and meta-analysis. 13,		0
4	SARS-CoV-2 Exploits Non-Canonical Autophagic Processes to Replicate, Mature, and Egress the Infected Vero E6 Cells. **2022**, 11, 1535		0
3	Severe COVID-19 A Review of Suggested Mechanisms Based on the Role of Extracellular Matrix Stiffness. **2023**, 24, 1187		0
2	A Three-Dimensional Xeno-Free Culture Condition for Wharton Jelly-Mesenchymal Stem Cells: The Pros and Cons. **2023**, 24, 3745		0
1	An integrated approach of high-performance liquid chromatography mass spectrometry-based chemical profiling, network pharmacology, and molecular docking to reveal the potential mechanisms of Qishen Gubiao granules for treating coronavirus disease 2019. 2200953		0